



---

**ASX Announcement and Media Release**

**Wednesday, December 02, 2009**

**SciGen Ltd**

**CHANGES IN THE BOARD OF DIRECTORS**

The Board of Directors of SciGen Limited (ASX: SIE) (the “**SciGen**”) announces major changes in Board.

**RESIGNATION OF CHAIRMAN & CEO**

Following his resignation as the CEO of the Company, Mr Allerhand had also resigned as Chairman and Director of the Company. Mr Allerhand had agreed to assist in the handover of his duties and to stay on with the Company until 28 February 2010.

Mr Allerhand leaves of his own accord. The Board thanks Mr Allerhand for his contribution to SciGen, especially in the successful restructuring of its operations.

**RESIGNATION OF NON-EXECUTIVE DIRECTORS**

Mr Janusz Guy and Mr Waldemar Krzewski resigned as Directors. The Board thanks both Mr Guy and Mr Krzewski for their contributions to SciGen.

**APPOINTMENT OF DIRECTOR & CHAIRMAN**

SciGen is pleased to announce the reappointment of Mr Ryszard Krauze as a Director of the Company. In addition, Mr Krauze will be the Chairman of the Company.

Mr Krauze is the founder, key shareholder and Chairman of the Polish biotechnological company Bioton SA – SciGen’s strategic investor since 2005. Today, Bioton leads a group of biotech and pharmaceutical companies operating in EU countries, Russia, China and Southeast Asia and is one of the world’s major manufacturer of recombinant human insulin. Since March 2005 Bioton is listed on the Warsaw Stock Exchange as part of the blue-chip WIG20 index. Bioton Group develops a portfolio of biotechnological products including among others human growth hormone sustained release. In June 2009 Bioton and SciGen have signed a 2 billion USD exclusive insulin supply and distribution agreement with Bayer

Schering Pharma for the China market. Mr Krauze was acting as the Vice-Chairman of the Board of Directors of SciGen from 2005 to 2008.

Mr Krauze is also through his investment company, Prokom Investments, a key shareholder in two other companies floated on the Warsaw Stock Exchange and specialized in oil exploration and production (Petrolinvest Group) and real-estate development (Polnord Group).

#### **APPOINTMENT OF CEO & DIRECTOR**

SciGen is pleased to announce the appointment of Mr Sławomir Ziegert as CEO and also as a Director of the Company.

Mr Ziegert, is a doctor, graduate of the Medical University in Gdańsk. He is the President of the Management Board and CEO of Bioton SA. He has been connected with the pharmaceutical industry for over sixteen years, working in Poland and abroad for such concerns as Eli Lilly, Egis Group (a part of Servier group) and Ipsen. He has business experience covering different sectors of the pharmaceutical industry, including biotechnology and in particular business development within the scope of endocrinology and treatment of diabetes.

From 1993 to 2004 Mr Sławomir Ziegert worked in the Polish branch of Eli Lilly, one of the world's leading pharmaceutical concerns and manufacturers of recombinant human insulin and insulin analogues, where he was responsible for the development of diabetes business, relations with the diabetes environment and governmental affairs. From 1998 to 2000 he was also Eli Lilly's Country Manager in Slovakia, supervising among others, the development of sale of insulins and antibiotics. He served also as the CEO of Egis Pharmaceuticals (a part of Servier group) with responsibility for the Baltic States area and as CEO of Ipsen Poland.

#### **APPOINTMENT OF NON EXECUTIVE DIRECTORS**

SciGen is pleased to announce the appointment of 2 non-executive directors –

##### **Mr Amol Shah**

Mr Amol Shah is the Managing Director of MJ Biopharm Pvt Ltd, an Indian based company possessing a modern facility in Mumbai for manufacturing of life saving products including Insulin. He focuses on overall supervision of the company and the development of strategic business alliances. From 1990 to 1995 he worked as a Director at Anglo Gulf Limited in Dubai where he was responsible for setting up of a new facility for manufacture of pesticides in Jebel Ali, Dubai and managing of new business collaboration with multinational companies for the production and sale of their products in the Middle East. In 1987 he also worked for Eli Lilly in UK.

##### **Mr Mateusz Kosecki**

Mr Mateusz Kosecki is a graduate of the Executive MBA Program of European University, Montreux, Switzerland. Mr Kosecki is the Managing Director for Eastern Europe, Asia and Pacific Region of Bioton S.A. and oversees the operations of the company in the region and is also responsible for the business development. Mr Kosecki possesses extensive experience in international business. From 1995 to 1996 he worked as the Marketing Manager in Lenex Company in Sofia, Bulgaria. From 1997 to 2001 he was Head of Foreign

Corporate Governance and Operations of Ciech S.A.. the biggest Polish chemical holding company. He has been connected with the pharmaceutical industry for 8 years. From 2002 to 2006 as Country Manager for Russia of the Polish pharmaceutical company Ciech Polfa, and from 2006 to 2009 as Regional Director for Eastern Europe in Bioton SA.

### **APPOINTMENT OF EXECUTIVE DIRECTORS**

SciGen is pleased to announce the appointment of 2 executive directors -

#### **Mr Martin Cooper**

Mr Martin Cooper is the Chief Financial Officer of the SciGen Group. Mr Cooper, a British Citizen, is based in Singapore. He qualified as a Chartered Accountant in 1990 with Deloitte & Touché and has an MBA from Henley Management College, Oxford, England.

Prior to joining SciGen in October 2006, Mr Cooper spent 6 years as the Group Finance Director for The Parkmead Group Plc. Parkmead is a Venture Capital company listed on the AIM in London. In addition to his role as FD he was also the company secretary and was a Non-Executive Director of a number of early stage high growth businesses.

Mr Cooper has extensive experience including restructuring private equity investments, preparation and appraisal of financial business models, restructuring of finance departments, maintaining financial controls in fast growth environments as well as substantial strategic and commercial experience.

#### **Ms Jenny Low**

Ms Jenny Low is the Senior Vice President & Corporate Secretary of the Company. Ms Low, who has been with the Company for over 18 years, is the longest service staff member and has been involved in many areas of the Company's operations, including the listing of the Company on ASX. Prior to her appointment as the Senior Vice President in October 2006, Ms Low was the Chief Financial Officer of the Company.

Ms Low, a chartered accountant, held senior accountancy positions in various companies in both Malaysia and Singapore. With over 30 years of accounting experience, Ms Low is well versed with accounting practices and tax laws of the Asia-Pacific region. Before joining SciGen in September 1991, Ms Low was with Abacus Distribution Systems Pte Ltd, a company owned jointly by the major airline companies in Asia

### **About SciGen**

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin, GCSF and Interferon Alpha 2b.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, Vietnam, China, India, Israel and Philippines, distribution channels in Taiwan, China, India, Pakistan, Thailand and Indonesia, manufacturing facilities in Israel, India and China and a contract manufacturer in Poland, Bioton S.A.

<b>For further information:</b> Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: <a href="mailto:gdunlop@scigen.com.au">gdunlop@scigen.com.au</a>	Mr Sławomir Ziegert CEO SciGen Ltd +65 6779 6638